Bristol Myers Squibb’s drug Augtyro received FDA approval for the treatment of solid tumors with a specific genetic signature known as NTRK gene fusion. This expanded approval allows for the treatment of adults and adolescents with advanced, untreated tumors that have no other alternative therapy. Augtyro is a tyrosine kinase inhibitor that works by blocking enzymes key to cancer growth. Clinical trials showed positive response rates in TKI-naïve and previously treated patients, with a median duration of response not yet reached. The accelerated approval is based on overall response rates, and additional clinical data may be required to confirm safety and efficacy.
Source link
New FDA Nod Brings Bristol Myers Squibb Cancer Drug to a Wider Range of Solid Tumors
